Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 6.92 USD -0.14%
Market Cap: 373.5m USD

Relative Value

The Relative Value of one FULC stock under the Base Case scenario is 4.35 USD. Compared to the current market price of 6.92 USD, Fulcrum Therapeutics Inc is Overvalued by 37%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FULC Relative Value
Base Case
4.35 USD
Overvaluation 37%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
82
vs Industry
49
Median 3Y
32.5
Median 5Y
37.5
Industry
2.5
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-5.1
Industry
21.2
Forward
-5.8
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-6.3
Industry
16.3
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-6.2
Industry
23.8
vs History
60
vs Industry
68
Median 3Y
1.4
Median 5Y
1.9
Industry
2.1
vs History
71
vs Industry
3
Median 3Y
3.2
Median 5Y
13.8
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
vs Industry
49
Median 3Y
-0.8
Median 5Y
-2.1
Industry
12.5
Forward
-1.5
vs History
vs Industry
48
Median 3Y
-0.7
Median 5Y
-2
Industry
15.9
Forward
-1.6
vs History
vs Industry
14
Median 3Y
-1
Median 5Y
-2.6
Industry
14.6
vs History
vs Industry
18
Median 3Y
-1
Median 5Y
-2.6
Industry
17.2
vs History
55
vs Industry
6
Median 3Y
4.1
Median 5Y
8.7
Industry
1.8

Multiples Across Competitors

FULC Competitors Multiples
Fulcrum Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
373.5m USD 4.7 -38.4 -7.3 -6.7
US
Eli Lilly and Co
NYSE:LLY
739.9B USD 15.1 66.6 35.8 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.3B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.1 13.2 15.2
CH
Roche Holding AG
SIX:ROG
207.2B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
192.4B CHF 4.5 18.8 11.1 14.8
UK
AstraZeneca PLC
LSE:AZN
160.1B GBP 4 28.2 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
203.6B USD 3.2 11.7 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
144.3B USD 2.3 18.3 7.8 10.9
P/E Multiple
Earnings Growth PEG
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
Average P/E: 25.6
Negative Multiple: -38.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.6
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
Average EV/EBITDA: 433.7
Negative Multiple: -7.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
11.1
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
Average EV/EBIT: 1 867.3
Negative Multiple: -6.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.1
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.2
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.8
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1